Today: 19 April 2026
UniFirst Corporation Stock Jumps After Report Says Cintas Is Nearing a Deal Above $275 a Share
6 March 2026
1 min read

UniFirst Corporation Stock Jumps After Report Says Cintas Is Nearing a Deal Above $275 a Share

NEW YORK, March 6, 2026, 09:02 (EST)

Cintas is closing in on a deal to acquire workwear rival UniFirst, according to Bloomberg Law, which reported Thursday that negotiations are ongoing over a price tag north of $275 per share—or about $5.2 billion—the same offer Cintas put forward in December. UniFirst shares jumped 13.6% in premarket action Friday.

This report brings fresh momentum to a deal that hit pause back on March 24, 2025. That’s when Cintas CEO Todd Schneider said negotiations with UniFirst had failed to move forward on crucial terms. UniFirst, for its part, had noted on Dec. 22 that its board was still weighing Cintas’ non-binding proposal with help from external advisers.

Both companies provide uniforms, safety supplies, and facility products to business clients throughout North America. Cintas, back in December, said merging would boost processing muscle and route density—meaning more stops per delivery run—and push the combined customer total well past 1 million businesses across the U.S. and Canada.

Back in December, Cintas put forward a $275-per-share cash offer for UniFirst common and Class B stock, valuing the company at roughly $5.2 billion. That’s a 64% premium over UniFirst’s average price across the past 90 days. Schneider said at the time the merger would deliver “considerable benefits for customers, employee-partners and shareholders.” Default

On Dec. 22, UniFirst disclosed that it had brought in Goldman Sachs and J.P. Morgan as financial advisors to the board, with Paul Hastings handling legal matters. The company noted it was “carefully reviewing and evaluating” the offer, telling shareholders there was no immediate action required. GlobeNewswire

UniFirst continues to stick with its own strategy. Back in January, first-quarter revenue came in at $621.3 million, up 2.7%. Net income didn’t keep pace, dropping to $34.4 million from $43.1 million, as increased spending on growth initiatives and digital upgrades trimmed margins. CEO Steven Sintros described the push as a way to “accelerate growth and enhance operational efficiency.” Full-year guidance remains unchanged. GlobeNewswire

Cintas has been pursuing an agreement since 2022. On Jan. 7, 2025, Reuters reported UniFirst turned down Cintas’s $275-per-share offer for a second time; after stepping back in March, Cintas came back with another proposal in December.

No deal yet. Even if one is reached, it still hinges on a binding contract and shareholder sign-off, and thanks to UniFirst’s dual-class setup, Class B shares carry ten votes apiece, while common stock holders get just one per share.

Antitrust concerns loom large here. Back in December, Cintas introduced a $350 million reverse termination fee—essentially a payout to UniFirst if regulators shut the deal down. Still, according to Bloomberg Law, discussions are private and the terms aren’t set in stone; there’s room for changes, or even for the whole thing to collapse.

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Robinhood Markets cuts RVI IPO size as premium card push targets wealthier investors
Previous Story

Robinhood Markets cuts RVI IPO size as premium card push targets wealthier investors

Okta Stock Jumps After Q4 Beat, but Slowest Growth Forecast Since IPO Still Looms
Next Story

Okta Stock Jumps After Q4 Beat, but Slowest Growth Forecast Since IPO Still Looms

Go toTop